Literature DB >> 7543458

Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines.

J Southgate1, L K Trejdosiewicz, B Smith, P J Selby.   

Abstract

CD44 core and splice variant exon expression was investigated in the stratified transitional epithelium of the urinary tract and in normal and malignant bladder epithelial cell lines in vitro. Antibodies against core CD44 epitopes and splice exon variants v3, v4/5, v5 and v6 showed an intense reaction in the basal and lower intermediate urothelial cell layers, which was consistently lost from the upper intermediate and superficial cell layers. Seven independent cell lines established from normal human urothelium expressed complex multiple-spliced CD44 mRNA transcripts when tested by RT-PCR and were positive with antibodies against CD44 core epitopes and splice variants v3, v4/5, v5 and v6. Of the 13 bladder-carcinoma cell lines, all were positive for CD44 core. The more differentiated cell lines had retained some splice-variant antibody reactivity and showed multiple but less complex CD44 mRNA transcript patterns, compared with normal cells. Anaplastic cell lines did not react with variant antibodies and did not contain multiple-spliced CD44 transcripts. These data suggest that loss of alternatively-spliced CD44 may reflect a selection pressure in the evolution of anaplastic bladder cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543458     DOI: 10.1002/ijc.2910620415

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  CD44 and the adhesion of neoplastic cells.

Authors:  Z Rudzki; S Jothy
Journal:  Mol Pathol       Date:  1997-04

2.  Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.

Authors:  V Toma; D Hauri; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; T C Gasser; G Sauter; J Roth
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

3.  Expression of CD44 on bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis.

Authors:  S M Cruickshank; J Southgate; J I Wyatt; P J Selby; L K Trejdosiewicz
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

Review 4.  CD44 cell adhesion molecules.

Authors:  S Goodison; V Urquidi; D Tarin
Journal:  Mol Pathol       Date:  1999-08

5.  Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.

Authors:  Wei-Chun Weng; Yu-Hui Huang; Shun-Fa Yang; Shian-Shiang Wang; Wu-Hsien Kuo; Chao-Wen Hsueh; Ching-Hsuan Huang; Ying-Erh Chou
Journal:  Tumour Biol       Date:  2015-12-12

6.  Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.

Authors:  Qianxing Mo; Fotis Nikolos; Fengju Chen; Zoe Tramel; Yu-Cheng Lee; Kazukuni Hayashi; Jing Xiao; Jianjun Shen; Keith Syson Chan
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

7.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

8.  Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer.

Authors:  D C Gotley; J Fawcett; M D Walsh; J A Reeder; D L Simmons; T M Antalis
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

9.  Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?

Authors:  G Humphrey; D L Hazel; K MacLennan; I Lewis
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  IL22 regulates human urothelial cell sensory and innate functions through modulation of the acetylcholine response, immunoregulatory cytokines and antimicrobial peptides: assessment of an in vitro model.

Authors:  Phong T Le; Meghan M Pearce; Shubin Zhang; Edward M Campbell; Cynthia S Fok; Elizabeth R Mueller; Cynthia A Brincat; Alan J Wolfe; Linda Brubaker
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.